查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1229676

亞斯伯格症候群的全球市場:至2030年的預測

Asperger Syndrome Market Research Report Forecast Till 2030
出版日期: | 出版商: Market Research Future | 英文 100 Pages | 商品交期: 請詢問到貨日

價格

全球亞斯伯格症候群的市場規模，預計至2030年的調查期間中以3.70％的年複合成長率成長。由於精神藥理學的進步，可用目標藥物療法進行，因此，更好的藥物治療的可用性推動市場的成長。

本報告提供全球亞斯伯格症候群市場相關調查分析，市場動態，市場分析，競爭情形，企業簡介等系統性資訊。

目錄

第1章 報告開端

第2章 市場簡介

  • 定義
  • 調查範圍
    • 調查目的
    • 假設
    • 限制事項

第3章 調查手法

  • 簡介
  • 1次調查
  • 2次調查
  • 市場規模的估計

第4章 市場動態

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題
  • 宏觀經濟指標
  • 技術趨勢與評估

第5章 市場要素分析

  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭的激烈程度
  • 價值鏈分析
  • 投資可行性分析
  • 價格分析

第6章 全球亞斯伯格症候群市場:各診斷

  • 簡介
  • DSM-IV
  • 鑑別診斷
  • 兒童亞斯伯格症候群檢驗
  • GILLIAM亞斯伯格症量表(GADS)
  • KRUG亞斯伯格症指數(KADI)
  • 其他

第7章 全球亞斯伯格症候群市場:各治療

  • 簡介
  • 父母的教育和培訓
  • 社群技術訓練
  • 語言療法
  • 應用行為分析(ABA)
  • 投藥

第8章 全球亞斯伯格症候群市場:各終端用戶

  • 簡介
  • 醫院
  • 診所
  • 診斷中心
  • 藥妝店
  • 藥局
  • 其他

第9章 全球亞斯伯格症候群市場:各地區

  • 簡介
  • 南北美洲
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 大韓民國
    • 其他的亞太地區
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 阿曼
    • 科威特
    • 卡達
    • 其他的中東及非洲

第10章 企業形勢

  • 簡介
  • 市場佔有率分析
  • 主要的開發與策略
    • 主要的開發

第11章 企業簡介

  • ELI LILLY AND COMPANY'S
  • SHIRE
  • JAZZ PHARMACEUTICALS
  • PFIZER
  • GLAXOSMITHKLINE
  • FOREST LABORATORIES, INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • 其他

第12章 MRFR的結論

  • 主要調查結果
    • 從CEO的觀點
    • 未滿足需求
  • 值得注意的主要企業
  • 亞斯伯格症候群產業的預測

第13章 附錄

Product Code: MRFR/Pharma/4383-HCR

Market Overview

The Asperger Syndrome market should enlist a CAGR of 3.70% during the forecast time period. Asperger's syndrome is furthermore called Intellectually lopsided Reach Issue which generally begins in youthfulness and continues to stay till death. There are several vital differentiations not entirely set in stone to have a chemical imbalance and those with Asperger's syndrome. A couple of clinical specialists have acknowledged that Asperger's syndrome is a milder type of chemical imbalance. Overall, the secondary effects showed up in Asperger's syndrome are milder; in any case, the children not set in stone to have a chemical imbalance range tangle.

The rising regularity of the chemical imbalance and the extensive variety of the condition are the fundamental clarifications behind the overall advancement of the Asperger syndrome industry. Lately, World Prosperity Affiliation has communicated that there were around 1 of each not set in stone to have a mental imbalance. Progressing assessments show that there are a couple of explanations behind the syndrome, for instance, unforeseen work, a youth brought into the world not long after its kinfolk, family heritage, more prepared gatekeepers, any mental issue, epilepsy, or malignant growth in the psyche. A rising number of purposes behind the condition and normal components have expanded the overall Asperger syndrome marked improvement of late.

The degrees of progress in Psychopharmacology concerning arranging their medications to target unequivocal patients and having less delayed consequences yet more suitable have expanded the overall advancement of the Asperger Syndrome industry recently. While there are still many cases where the necessary medication is not supplied, the increased frequency of chemical imbalance range mix and Asperger syndrome is having a significant impact on the recent growth of the Asperger syndrome market.

Market Segmentation

Asperger Syndrome, Pervasive Developmental Disorder, Autistic Disorder, and Disintegrative Disorder are the several types of disorders that make up the market.

The market is divided into four categories based on deployment: Applied Behavior Analysis (ABA), Speech and Language Therapy, and Occupation Therapy.

Drug Treatments, Antipsychotic Medications, SSRIs, Stimulants, and Sleep Medicine are all included in the Treatment part.

Regional Analysis

America is likely to lead the Asperger Syndrome industry. Over 3.5 million Americans are living with the condition as per a new report. In no less than 10 years, a few locales in America exhibits more than a 119.4% increment concerning the number of cases. The costs brought about in treating the condition have expanded by over USD 236-262 billion lately. Such factors have expanded the general development of the Asperger Syndrome industry.

The administrative drives and presence of driving market players in Europe are the essential purposes behind the development of the Asperger Syndrome industry in Europe. Ease in the repayment approaches and propelling foundation of the medical services places are reinforcing the development of the Asperger Syndrome industry.

Major Players

Asperger Syndrome Market Competitors are Eli Lilly and Company, Shire, Jazz Pharmaceuticals, Pfizer, GlaxoSmithKline, Forest Laboratories, Johnson & Johnson, Bristol-Myers Squibb, Otsuka pharmaceutical, and AstraZeneca.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS:

CHAPTER 1. REPORT PROLOGUE

CHAPTER 2. MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
    • 2.2.1 RESEARCH OBJECTIVE
    • 2.2.2 ASSUMPTIONS
    • 2.2.3 LIMITATIONS

CHAPTER 3. RESEARCH METHODOLOGY

  • 3.1 INTRODUCTION
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION

CHAPTER 4. MARKET DYNAMICS

  • 4.1 DRIVERS
  • 4.2 RESTRAINTS
  • 4.3 OPPORTUNITIES
  • 4.4 CHALLENGES
  • 4.5 MACROECONOMIC INDICATORS
  • 4.6 TECHNOLOGY TRENDS & ASSESSMENT

CHAPTER 5. MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
  • 5.3 INVESTMENT FEASIBILITY ANALYSIS
  • 5.4 PRICING ANALYSIS

CHAPTER 6. GLOBAL ASPERGER SYNDROME MARKET, BY DIAGNOSIS

  • 6.1 INTRODUCTION
  • 6.2 DSM-IV
    • 6.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.3 DIFFERENTIAL DIAGNOSIS
    • 6.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.4 CHILDHOOD ASPERGER SYNDROME TEST
    • 6.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.5 GILLIAM ASPERGER'S DISORDER SCALE (GADS)
    • 6.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.6 KRUG ASPERGER'S DISORDER INDEX (KADI)
    • 6.6.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.7 OTHERS
    • 6.7.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 7. GLOBAL ASPERGER SYNDROME MARKET, BY TREATMENT

  • 7.1 INTRODUCTION
  • 7.2 PARENT EDUCATION & TRAINING
    • 7.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.3 SOCIAL SKILLS TRAINING
    • 7.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.4 SPEECH-LANGUAGE THERAPY
    • 7.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.5 APPLIED BEHAVIORAL ANALYSIS (ABA)
    • 7.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.6 MEDICATION
    • 7.6.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 8. GLOBAL ASPERGER SYNDROME MARKET, BY END-USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    • 8.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.3 CLINICS
    • 8.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.4 DIAGNOSTIC CENTERS
    • 8.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.5 DRUG STORES
    • 8.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.6 PHARMACIES
    • 8.6.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.7 OTHERS
    • 8.7.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 9. GLOBAL ASPERGER SYNDROME MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 AMERICAS
    • 9.2.1 NORTH AMERICA
      • 9.2.1.1 U.S.
      • 9.2.1.1 CANADA
    • 9.2.2 SOUTH AMERICA
  • 9.3 EUROPE
    • 9.3.1 WESTERN EUROPE
      • 9.3.1.1 GERMANY
      • 9.3.1.2 FRANCE
      • 9.3.1.3 ITALY
      • 9.3.1.4 SPAIN
      • 9.3.1.5 U.K.
      • 9.3.1.6 REST OF WESTERN EUROPE
    • 9.3.2 EASTERN EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 REPUBLIC OF KOREA
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 THE MIDDLE EAST & AFRICA
    • 9.5.1 UNITED ARAB EMIRATES
    • 9.5.2 SAUDI ARABIA
    • 9.5.3 OMAN
    • 9.5.4 KUWAIT
    • 9.5.5 QATAR
    • 9.5.6 REST OF THE MIDDLE EAST & AFRICA

CHAPTER 10 COMPANY LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS
  • 10.3 KEY DEVELOPMENT & STRATEGIES
    • 10.3.1 KEY DEVELOPMENTS

CHAPTER 11 COMPANY PROFILES

  • 11.1 ELI LILLY AND COMPANY'S
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 TYPES OVERVIEW
    • 11.1.3 FINANCIALS
    • 11.1.4 SWOT ANALYSIS
  • 11.2 SHIRE
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 TYPES OVERVIEW
    • 11.2.3 FINANCIAL OVERVIEW
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
  • 11.3 JAZZ PHARMACEUTICALS
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 TYPES OVERVIEW
    • 11.3.3 FINANCIAL OVERVIEW
    • 11.3.4 KEY DEVELOPMENT
    • 11.3.5 SWOT ANALYSIS
  • 11.4 PFIZER
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 TYPES/BUSINESS SEGMENT OVERVIEW
    • 11.4.3 FINANCIAL OVERVIEW
    • 11.4.4 KEY DEVELOPMENT
    • 11.4.5 SWOT ANALYSIS
  • 11.5 GLAXOSMITHKLINE
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 TYPES OVERVIEW
    • 11.5.3 FINANCIAL OVERVIEW
    • 11.5.4 KEY DEVELOPMENTS
  • 11.6 FOREST LABORATORIES, INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 TYPES OVERVIEW
    • 11.6.3 FINANCIAL OVERVIEW
    • 11.6.4 KEY DEVELOPMENTS
  • 11.7 JOHNSON & JOHNSON SERVICES, INC.
    • 11.7.1 OVERVIEW
    • 11.7.2 TYPES OVERVIEW
    • 11.7.3 FINANCIALS
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
  • 11.8 OTHERS

CHAPTER 12 MRFR CONCLUSION

  • 12.1 KEY FINDINGS
    • 12.1.1 FROM CEO'S VIEW POINT
    • 12.1.2 UNMET NEEDS OF THE MARKET
  • 12.2 KEY COMPANIES TO WATCH
  • 12.3 PREDICTION OF ASPERGER SYNDROME INDUSTRY

CHAPTER 13 APPENDIX

LIST OF TABLES

  • TABLE 1 ASPERGER SYNDROME INDUSTRY SYNOPSIS, 2022-2030
  • TABLE 2 ASPERGER SYNDROME MARKET ESTIMATES & FORECAST, 2022-2030, (USD MILLION)
  • TABLE 3 ASPERGER SYNDROME MARKET, BY REGION, 2022-2030, (USD MILLION)
  • TABLE 4 ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 5 ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 6 ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 7 NORTH AMERICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 8 NORTH AMERICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 9 NORTH AMERICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 10 U.S. ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 11 U.S. ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 12 U.S. ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 13 CANADA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 14 CANADA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 15 CANADA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 16 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 17 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 18 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 19 EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 20 EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 21 EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 22 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 23 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 24 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 25 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 26 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 27 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 28 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 29 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 30 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 31 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 32 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 33 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 SEGMENTATION FOR THE ASPERGER SYNDROME MARKET
  • FIGURE 3 SEGMENTATION MARKET DYNAMICS FOR THE ASPERGER SYNDROME MARKET
  • FIGURE 4 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY DIAGNOSIS, 2022
  • FIGURE 5 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY TREATMENT, 2022
  • FIGURE 6 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY END-USER, 2022
  • FIGURE 7 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY REGION, 2022
  • FIGURE 8 NORTH AMERICA ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 9 EUROPE ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 10 ASIA PACIFIC ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 11 MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 12 GLOBAL ASPERGER SYNDROME MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
  • FIGURE 13 ELI LILLY AND COMPANY'S: KEY FINANCIALS
  • FIGURE 14 ELI LILLY AND COMPANY'S: SEGMENTAL REVENUE
  • FIGURE 15 ELI LILLY AND COMPANY'S: GEOGRAPHICAL REVENUE
  • FIGURE 16 SHIRE: KEY FINANCIALS
  • FIGURE 17 SHIRE: SEGMENTAL REVENUE
  • FIGURE 18 SHIRE: GEOGRAPHICAL REVENUE
  • FIGURE 19 JAZZ PHARMACEUTICALS: KEY FINANCIALS
  • FIGURE 20 JAZZ PHARMACEUTICALS: SEGMENTAL REVENUE
  • FIGURE 21 JAZZ PHARMACEUTICALS: GEOGRAPHICAL REVENUE
  • FIGURE 22 PFIZER: KEY FINANCIALS
  • FIGURE 23 PFIZER: SEGMENTAL REVENUE
  • FIGURE 24 PFIZER: GEOGRAPHICAL REVENUE
  • FIGURE 25 GLAXOSMITHKLINE: KEY FINANCIALS
  • FIGURE 26 GLAXOSMITHKLINE: SEGMENTAL REVENUE
  • FIGURE 27 GLAXOSMITHKLINE GEOGRAPHICAL REVENUE
  • FIGURE 28 FOREST LABORATORIES, INC.: KEY FINANCIALS
  • FIGURE 29 FOREST LABORATORIES, INC.: SEGMENTAL REVENUE
  • FIGURE 30 FOREST LABORATORIES, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS
  • FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE
  • FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: GEOGRAPHICAL REVENUE